PT - JOURNAL ARTICLE AU - Nathan J. Edwards AU - Rebecca Widrick AU - Richard Potember AU - Mike Gerschefske TI - Quantifying Respiratory Airborne Particle Dispersion Control Through Improvised Reusable Masks: The Physics of Non-Pharmaceuptical Interventions for Reducing SARS-COV-2 (COVID-19) Airborne Transmision AID - 10.1101/2020.07.12.20152157 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.12.20152157 4099 - http://medrxiv.org/content/early/2020/08/17/2020.07.12.20152157.short 4100 - http://medrxiv.org/content/early/2020/08/17/2020.07.12.20152157.full AB - Background For much of the SARS-CoV-2 (COVID-19) pandemic, many countries have struggled to offer definitive guidance on the wearing of masks or face coverings to reduce the highly infectious disease transmission resulting from a lack of compelling evidence on the effectiveness of communities wearing masks, and slow acceptance that aerosols are a primary SARS-CoV-2 disease transmission mechanism. Recent studies have shown that masks have been effective in several countries and populations, leaving only a lack of quantitative data on the control of airborne dispersion from human exhalation. This current study specifically has the objective to quantify the effectiveness of non-medical grade washable masks or face coverings in controlling airborne dispersion from exhalation (both droplet and aerosol) by measuring changes in direction, particle cloud velocities, and concentration.Design This randomized effectiveness study used a 10% NaCl nebulized polydisperse particle solution (0.3 μm up to 10 μm in size) delivered by an exhalation simulator to conduct 94 experiment runs with combinations of 8 different fabrics, 5 mask designs, and airflows for both talking and coughing. Multiple particle sensors were instrumented to measure reduction in aerosol dispersion.Results Three-way multivariate analysis of variance establishes that fabric, mask design, and exhalation breath level have a statistically significant effect on changing direction, reducing velocity, or concentrations of airborne particles (Fabric: P = < .001, Wilks’ Λ = .000; Mask design: P = < .001, Wilks' Λ = .000; Breath level: P = < .001, Wilks' Λ = .004). There were also statistically significant interaction effects between combinations of all primary factors.Conclusions and Relevance The application of facial coverings or masks can significantly reduce the airborne dispersion of aerosolized particles from exhalation by diffusing the particle cloud direction and slow down its travel speed. Consequently, the results indicate that wearing masks when coupled with social distance can decrease the potentially inhaled dose of SARS-CoV-2 aerosols or droplets especially where infectious contaminants may exist in shared air spaces. The conclusion is well aligned with the concept of “time-distance-shielding” from hazardous materials emergency response. However, the effectiveness varies greatly between the specific fabrics and mask designs used.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by independent research and development funding provided by the author's organization, The MITRE Corporation. Copyright 2020 The MITRE Corporation. ALL RIGHTS RESERVED. Approved for Public Release; Distribution Unlimited. Public Release Case Number 20-1583Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human participants, IRB not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEmpirical data may be made available by formal request to author's organization